Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

NCT00096525

Kidney Cancer

COMPLETED PHASE2

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

NCT01057121

COMPLETED PHASE1/PHASE2

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00604721

Adult Primary Hepatocellular Carcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer +1 more

COMPLETED PHASE2

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

NCT02780310

Adenoid Cystic Carcinoma

ACTIVE_NOT_RECRUITING PHASE2

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

NCT01375569

Hepatocellular Carcinoma Hepatocellular Cancer Carcinoma, Hepatocellular

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lenalidomide

Group Type EXPERIMENTAL

lenalidomide

Intervention Type DRUG

25 mg po qd x 21 days then 1 week off equals one cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lenalidomide

25 mg po qd x 21 days then 1 week off equals one cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

revlimid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pathologically confirmed HCC or triple phase CT consistent with HCC in a patient with known cirrhosis and AFP \> 200 ng/ml.
2. Disease not amenable to curative surgical resection
3. Patients must have been previously treated with sorafenib. Patients who are unable to receive sorafenib due to financial reasons are also eligible.
4. All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
5. No previous thalidomide.
6. Patients must have radiologically assessable tumor.
7. ECOG performance status of 0-2 at study entry.
8. Understand and voluntarily sign an informed consent form.
9. Age \>18 years at the time of signing the informed consent form.
10. Able to adhere to the study visit schedule and other protocol requirements.
11. Laboratory test results within these ranges:

* Absolute neutrophil count \> 1000/mm3
* Platelet count \> 60,000/mm3
* Serum creatinine \> 2.0 mg/dL
* Total bilirubin \> 4 mg/dL
* AST (SGOT) and ALT (SGPT) \> 5 x ULN.
12. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Appendix: H Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, AND also Appendix: F Education and Counseling Guidance Document
13. Disease free of prior malignancies for \> 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast

Exclusion Criteria

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
4. Use of any other experimental drug or therapy within 28 days of baseline.
5. Known hypersensitivity to thalidomide.
6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
7. Any prior use of lenalidomide.
8. Concurrent use of other anti-cancer agents or treatments.
9. Known positive for HIV. (The effect of immune modulation of lenalidomide on patients who are HIV positive is unknown).

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No